PTC Therapeutics has received a $1 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for the discovery of antiviral agents for the treatment of dengue fever. The one-year grant will support research for promising compounds identified by PTC’s proprietary GEMS (Gene Expression Modulation by Small-molecules) technology that demonstrate activity against the dengue virus (DENV).   PTC has established a cell-based DEN...